DEBT (Tables)

6 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Schedule of Long-Term Debt and Effective Interest Rates

Long-term debt as of March 31, 2024 and September 30, 2023 is detailed in the table below.

	March 31, 2024		September 30, 2023
Seller Note – Bolder BioPath (Related party)	$	489	$	602
Seller Note – Preclinical Research Services	503		541
Seller Payable - Orient BioResource Center	3,680		3,649
Seller Note – Histion (Related party)	156		229
Seller Note – Protypia (Related party)	—		400
Economic Injury Disaster Loan	—		140
Convertible Senior Notes	113,716		110,651
Term Loan Facility, DDTL and Incremental Term Loans	271,849		272,930
Total debt before unamortized debt issuance costs	$	390,393	$	389,142
Less: Debt issuance costs not amortized	(9,760)		(11,397)
Total debt, net of unamortized debt issuance costs	$	380,633	$	377,745
Less: Current portion	$	(380,358)	$	(7,950)
Total Long-term debt	$	275	$	369,795

Below are the weighted-average effective interest rates for the loans available under the Credit Agreement (as defined below):

	Three Months Ended March 31,				Six Months Ended March 31,
	2024		2023		2024		2023
Effective interest rates:
Term Loan	11.06	%	10.40	%	11.30	%	10.32	%
Initial DDTL	11.05	%	10.45	%	11.29	%	10.35	%
Additional DDTL	11.17	%	10.68	%	11.42	%	11.07	%